BridgeBio Pharma (BBIO) PT Raised to $96 at BofA Securities

April 28, 2026 3:23 PM

BofA Securities analyst Jason Zemansky raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $96.00 (from $95.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found